N. Stallard, P. F. Thall, and J. Whitehead, Decision theoretic designs for phase II clinical trials with multiple outcomes, Nat Rev Drug Discov, vol.55, pp.27-36, 1989.

H. C. Brunier and J. Whitehead, Sample sizes for phase II clinical trials derived from Bayesian decision theory, Stat Med, vol.13, pp.2493-502, 19945.

N. Stallard, Decision-theoretic designs for phase II clinical trials allowing for competing studies, Biometrics, vol.59, pp.402-411, 20036.

N. Stallard, J. Whitehead, and S. Todd, Stopping rules for phase II studies, Br J Clin Pharmacol, vol.51, pp.523-532, 2001.

P. F. Thall and R. Simon, A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials, Control Clin Trials, vol.15, pp.463-81, 19948.

P. F. Thall, R. M. Simon, and E. H. Estey, New statistical strategy for monitoring safety and efficacy in single-arm clinical trials, J Clin Oncol, vol.14, pp.296-303, 19969.

A. K. Gupta and S. Nadarajah, Handbook Of Beta Distribution And Its Applications, 200410.

S. B. Tan and D. Machin, Bayesian two-stage designs for phase II clinical trials, Stat Med, vol.21, 1991.

P. F. Thall, E. H. Estey, D. J. Spiegelhalter, K. R. Abrams, J. P. Myles et al., A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation, Stat Med, vol.12, p.15, 1993.

M. S. Mayo and B. J. Gajewski, FDA FaDA: Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials -Draft Guidance for Industry and FDA Staff, Control Clin Trials, vol.25, p.17, 2004.

D. Farge, J. P. Marolleau, and S. Zohar, Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study, Br J Haematol, vol.119, pp.726-765, 200218.

S. Zohar and S. Chevret, The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies, Stat Med, vol.20, pp.2827-2870, 200119.

C. Chen and K. Chaloner, A Bayesian stopping rule for a single arm study: With a case study of stem cell transplantation, Stat Med, vol.25, pp.2956-66, 200620.

P. Rousselot, J. Larghero, and B. Arnulf, A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients, Berger JO: Statistical decision theory and Bayesian analysis, vol.18, pp.1518-1539, 1996.